Sara Willa Ernst is a reporter with The Cancer Letter. She joined the publication in 2025.


Before joining The Cancer Letter, Sara reported on health in Texas both as a freelance journalist based in Austin and the health reporter at the NPR station in Houston, where she produced two investigative podcasts "Hot Stops" and "Below the Waterlines." The latter won her two regional Murrow awards in 2023.


Her bylines have appeared in publications such as NPR, The Texas Standard, WHYY's The Pulse, WBUR's Here and Now, Austin Free Press and the Austin Chronicle.


She graduated from Vanderbilt University with a bachelor's degree in Communications Studies in 2018.
Latest Stories
NCI releases names of members of ad hoc working group—filling the void left by BSA
NCI
NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.
AACR Cancer Progress Report makes the case for federal investment in cancer research
As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
NCAB approves five reissue concepts
The National Cancer Advisory Board approved five reissue concepts at a meeting Sept. 4. 
Cancer Policy
To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term. 
Trump administration unlawfully terminated grants from Harvard, federal judge rules
Cancer Policy
A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution. 
FDA will speed up public release of Complete Response Letters
Cancer Policy
FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login